Advanced search
Publication Cover
OncoTargets and Therapy Volume 11, 2018 - Issue
Submit an article Journal homepage
97
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

Hiroki OsumiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Daisuke TakahariDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]Correspondence[email protected]
,
Keisho ChinDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Mariko OguraDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Takashi IchimuraDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Takeru WakatsukiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Takeshi SuzukiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Yumiko OtaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Izuma NakayamaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Akira OokiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Mitsukuni SuenagaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
,
Eiji ShinozakiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
&
Kensei YamaguchiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, [email protected]
 show all
Pages 8301-8307 | Published online: 23 Nov 2018

References

  • Japan Ministry of Health, Labour and WelfareVital Statistics of Japan Ministry of Health, Labour and Welfare Available from: http://www.mhlw.go.jp/toukei/list/81-1.htmlAccessed August 27, 2018
  • Center for Cancer Control and Information Services Available from: http://ganjoho.jp/reg_stat/index.htmlAccessed August 27, 2018
  • GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide2012 Available from: http://globocan.iarc.fr/Accessed April 2, 2018
  • ChauINormanARCunninghamDWatersJSOatesJRossPJMultivariate prognostic factor analysis in locally advanced and metastatic esophagogastric cancer – pooled analysis from three multicenter, randomized, controlled trials using individual patient dataJ Clin Oncol200422122395240315197201
  • KooDHRyooBYKimHJA prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous modelsCancer Chemother Pharmacol201168491392121290247
  • AjaniJAD’AmicoTAAlmhannaKGastric cancer, version 3.2016, NCCN clinical practice guidelines in oncologyJ Natl Compr Canc Netw201614101286131227697982
  • SmythECVerheijMAllumWGastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v38v4927664260
  • BokuNYamamotoSFukudaHFluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 studyLancet Oncol200910111063106919818685
  • KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
  • YamadaYHiguchiKNishikawaKPhase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerAnn Oncol201526114114825316259
  • ShiraoKBokuNYamadaYRandomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)Jpn J Clin Oncol2013431097298024014884
  • Japanese Gastric Cancer AssociationJapanese gastric cancer treatment guidelines 2018 (ver. 5) [in Japanese]2018191
  • OhSYKwonHCLeeSA Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascitesJpn J Clin Oncol2007371293093518211984
  • IwasaSGotoMYasuiHMulticenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intakeJpn J Clin Oncol201242978779322782960
  • HaraHKadowakiSAsayamaMFirst-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intakeInt J Clin Oncol201823227528029039072
  • MasuishiTKadowakiSKondoMFOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasisAnticancer Res201737127037704229187492
  • HironakaSUedaSYasuiHRandomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trialJ Clin Oncol201331354438444424190112
  • YangXJHuangCQSuoTCytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trialAnn Surg Oncol20111861575158121431408

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.